AstraZeneca Hong Kong oversees both the Hong Kong and Macau markets and attaches a strong importance to them. Since our establishment, we have been focusing on identifying and bringing in the latest medical solutions as well as seeking ongoing business development. Over the years, we have been continually expanding our business in order to meet the growing demand of the markets.
We are building our new Global R&D Centre and Corporate Headquarters in Cambridge, UK. We begin the staged occupation of our new state-of-the-art-building from the end of 2018 and already have some 2,000 staff actively engaged in Cambridge's scientific, academic, clinical and business life. We are active in over 100 countries with growing presence in important emerging markets.
We are focused on returning to growth through a science-led innovation strategy. This is underpinned by a broad R&D platform, building a strong and balanced portfolio of primary care and specialty care medicines, accelerating key R&D programmes, engaging in targeted business development and leveraging our strong global commercial presence, particularly in emerging markets.
Our strategic priorities are to achieve scientific leadership, return to growth and be a great place to work. They reflect how we are working to achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines.
Backed by strong science and innovation, we are committed to sustainable development of our business and the delivery of a flow of new medicines that make a difference in the lives of patients in Hong Kong and around the world.
For more information about AstraZeneca, please go to: www.astrazeneca.com.